Trials / Unknown
UnknownNCT03619694
Role of MR Spectroscopy in Brain Tumors
Role of Magnetic Resonance Spectroscopy in Differentiating Brain Tumors
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
In order to come as close as possible to the correct diagnosis of CNS tumors, MRI is the long-standing accepted method of choice that can in some cases be supported by the use of CT to demonstrate calcification or bone destruction. In individual cases MRI spectroscopy can be helpful for the differentiation between neoplasms and inflammatory lesions or surveillance of tumor therapy, just as perfusion
Detailed description
Proton magnetic resonance spectroscopy (H-MRS) may be helpful in suggesting tumor histology and tumor grade and may better define tumor extension and the ideal site for biopsy compared with conventional magnetic resonance (MR) imaging. A multifunctional approach with diffusion-weighted imaging, perfusion-weighted imaging, and permeability maps, along with H-MRS, may enhance the accuracy of the diagnosis and characterization of brain tumors and estimation of therapeutic response. Integration of advanced imaging techniques with conventional MR imaging and the clinical history help to improve the accuracy, sensitivity, and specificity in differentiating tumors and nonneoplastic lesions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | MRI Spectroscopy | Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2018-09-01
- Completion
- 2018-10-01
- First posted
- 2018-08-08
- Last updated
- 2018-08-08
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03619694. Inclusion in this directory is not an endorsement.